This stock could soar at the end of the month, but is it worth the risk?
News & Analysis: Mirati Therapeutics
Due to the explosion in immuno-oncology in recent years, what was once a small scientific meeting near the end of the year has become a go-to event for drug developers.
Unfortunately, there were more of the latter.
Two presentations at the World Conference on Lung Cancer will make a big difference for at least four different drugmakers.
These three biotech stocks should be outstanding long-term growth vehicles.
Around $36 billion worth of biopharma acquisitions over the past few years suggests smaller might be better.
It looks like a target considered undruggable is actually within reach.
Lackluster results from Amgen's KRAS inhibitor program are clearing a path for Mirati's candidate.
Investors cheered the biotech's plans to move its lead candidate forward.
Shares tumbled after the company reported clinical data from an important phase 2 trial. Here's what investors need to know.